Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|A061402||Alliance||Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA4181||ECOG-ACRIN||A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients ≤ 70 years old with Untreated Mantle Cell Lymphoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|RTOG-0415||RTOG||A Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT versus Conventionally Fractionated 3D-CRT/IMRT in Patients with Favorable-Risk Prostate Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|E2112||ECOG||A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|E3A06||ECOG||Randomized Phase III Trial of Lenalidomide versus Observation Alone In Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma||Adult CIRB - Late Phase Emphasis||Available to Open|
|AALL0631||COG||A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy FLT3 Inhibition (CEP-701; Lestaurtinib; IND#76431; NSC#617807)||Pediatric CIRB||Available to Open|
|CALGB-40601||CALGB||Randomized Phase III Trial of Paclitaxel + Trastuzumab + Lapatinib Versus Paclitaxel + Trastuzumab as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1608||SWOG||Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|9899||ETCTN||A Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) inhibitor AT7519M in patients with Advanced Solid Tumors||Adult CIRB - Early Phase Emphasis||Available to Open|
|DCP-001||NCI||Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)||Cancer Prevention and Control CIRB||Available to Open|